- Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions - http://eyedocnews.com -

ACT Secures Approval to Proceed with Increased RPE Dosage for Patients in Clinical Trial for Dry AMD

Posted By Dr. Ari Weitzner On July 12, 2012 @ 11:24 am In Clinical Trials,Macular Degeneration,New Technologies,Stem Cell Therapies | Comments Disabled

Advanced Cell Technology, Inc. (OTCBB: ACTC) announced earlier this week that the Data and Safety Monitoring Board (DSMB), an independent group of medical experts closely monitoring the company’s three ongoing clinical trials, has authorized the company to move forward with enrollment and treatment of additional patients in its clinical trial for dry age-related macular degeneration (dry AMD). ACT will proceed with patient screening and enrollment for the second cohort, who, in keeping with trial protocol, will be injected with 100,000 retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs), as compared with the 50,000-cell dose used in the first cohort.

The trial is a prospective, open-label study, designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation into patients with dry AMD at 12 months.

Click here [1] to read the full press release.


Article printed from Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions: http://eyedocnews.com

URL to article: http://eyedocnews.com/006717-act-secures-approval-to-proceed-with-increased-rpe-dosage-for-patients-in-clinical-trial-for-dry-amd/

URLs in this post:

[1] Click here: http://www.advancedcell.com/news-and-media/press-releases/act-secures-approval-to-proceed-with-increased-rpe-dosage-for-patients-in-clinical-trial-for-dry-amd/index.asp

Copyright © 2008 Eye Doc Talk. All rights reserved.